[Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome].
Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients. Recent in vitro studies have demonstrated that this molecule was able to restore the anticoagulant action of annexin A5, which is reduced in presence of antiphospholipid antibodies. Hydroxychloroquine use may be a new approach of the prevention of thrombosis in the antiphospholipid syndrome, which remains to be validated by well-conducted clinical trials.
Szymezak
J
J
Service d'hématologie biologique, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75908 Paris cedex 15, France.
Ankri
A
A
Fischer
A-M
AM
Darnige
L
L
D017304:Annexin A5 / Q000097:blood / Q000187:drug effects; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004791:Enzyme Inhibitors / Q000097:blood; D019317:Evidence-Based Medicine; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy; D013927:Thrombosis / Q000276:immunology / Q000517:prevention & control*; D016896:Treatment Outcome
D017304:Annexin A5; D018501:Antirheumatic Agents; D015415:Biomarkers; D004791:Enzyme Inhibitors; D006886:Hydroxychloroquine